7,163
Views
89
CrossRef citations to date
0
Altmetric
Review

Influenza vaccination in the elderly

ORCID Icon, ORCID Icon, ORCID Icon, & ORCID Icon
Pages 540-549 | Received 27 Feb 2017, Accepted 13 Jun 2017, Published online: 04 Aug 2017

References

  • Udalkis L. Influenza. Available from: https://www.microbiologysociety.org/uploads/assets/uploaded/4e60089d-47b7-41af-95c3e71a2133d40f.pdf (accessed July 2017)
  • Lamb RA, Krug RM. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. eds. Fields Virology Vol 1, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins 2001:1487-1531.
  • Cox NJ, Subbarao K. Influenza. Lancet 1999; 354:1277-82; PMID:10520648; https://doi.org/10.1016/S0140-6736(99)01241-6.
  • Hayward AC, Fragaszy EB, Bermingham A, Wang L, Copas A, Edmunds WJ, Ferguson N, Goonetilleke N, Harvey G, Kovar J, et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med 2014; 2(6):445-54; PMID:24717637; https://doi.org/10.1016/S2213-2600(14)70034-7.
  • Rasmussen SA, Jamieson DJ, Uyeki TM. Effects of influenza on pregnant women and infants. Am J Obstet Gynecol 2012; 207(3 Suppl):S3-8; PMID:22920056; https://doi.org/10.1016/j.ajog.2012.06.068.
  • World Health Organization. Influenza. Available from: http://www.who.int/mediacentre/factsheets/2003/fs211/en (accessed July 2017)
  • ECDC. Flu season starts. Available from: https://ecdc.europa.eu/en/news-events/flu-season-starts (accessed July 2017)
  • Wong CM, Chan KP, Hedley AJ, Peiris JS. Influenza-associated mortality in Hong Kong. Clin Infect Dis 2004; 39:1611-7; PMID:15578360; https://doi.org/10.1086/425315.
  • Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med 2008; 121:258-64; PMID:18374680; https://doi.org/10.1016/j.amjmed.2007.10.040.
  • Thompson WW, Comanor L, Shay DK. Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis 2006; 194(Suppl 2):S82-91; PMID:17163394; https://doi.org/10.1086/507558.
  • Fleming DM, Taylor RJ, Haguinet F, Schuck-Paim C, Logie J, Webb DJ, Lustig RL, Matias G. Influenza-attributable burden in United Kingdom. Epidemiol Infect 2016; 144:537-47; PMID:26168005; https://doi.org/10.1017/S0950268815001119.
  • Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749-59; PMID:15858184; https://doi.org/10.1056/NEJMoa043951.
  • Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86; PMID:12517228; https://doi.org/10.1001/jama.289.2.179.
  • Gasparini R, Amicizia D, Lai P, Panatto D. Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly, Human Vaccines & Immunotherapeutics 2012; 8(1):21-28.
  • Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59(33):1057-62; PMID:20798667.
  • Reed C, Chaves SS, Daily Kirley P, Emerson R, Aragon D, Hancock EB, Butler L, Baumbach J, Hollick G, Bennett NM, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One 2015; 10(3):e0118369; PMID:25738736; https://doi.org/10.1371/journal.pone.0118369.
  • Linhart Y, Shohat T, Bromberg M, Mendelson E, Dictiar R, Green MS. Excess mortality from seasonal influenza is negligible below the age of 50 in Israel: implications for vaccine policy. Infection 2011; 39(5):399-404; PMID:21887527; https://doi.org/10.1007/s15010-011-0153-1.
  • Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25(27):5086-96; PMID:17544181; https://doi.org/10.1016/j.vaccine.2007.03.046.
  • Gasparini R, Amicizia D, Lai PL, Panatto D. Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly. Hum Vaccin Immunother 2012; 8(1):21-8; PMID:22252007; https://doi.org/10.4161/hv.8.1.17622.
  • Lai PL, Panatto D, Ansaldi F, Canepa P, Amicizia D, Patria AG, Gasparini R. Burden of the 1999-2008 seasonal influenza epidemics in Italy - Comparison with the H1N1v (A/California/07/09) pandemic. Hum Vaccin 2011; 7:217-25; PMID:21922688; https://doi.org/10.4161/hv.7.0.14607.
  • Xue Y, Kristiansen IS, de Blasio BF. Modeling the cost of influenza: the impact of missing costs of unreported complications and sick leave. BMC Public Health 2010; 10:724; PMID:21106057; https://doi.org/10.1186/1471-2458-10-724.
  • Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, Toniolo-Neto J, Drummond M, Weinstein M. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health 2007; 10(2):98-116; PMID:17391419; https://doi.org/10.1111/j.1524-4733.2006.00157.x.
  • Baguelin M, Jit M, Miller E, Edmunds WJ. Health and economic impact of the seasonal influenza vaccination programme in England. Vaccine 2012; 30(23):3459-62; PMID:22446636; https://doi.org/10.1016/j.vaccine.2012.03.019.
  • Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006; 31(1):72-9; PMID:16777545; https://doi.org/10.1016/j.amepre.2006.03.008.
  • Newall AT, Dehollain JP. The cost-effectiveness of influenza vaccination in elderly Australians: an exploratory analysis of the vaccine efficacy required. Vaccine 2014; 32(12):1323-5; PMID:24486359; https://doi.org/10.1016/j.vaccine.2014.01.017.
  • Ryan J, Zoellner Y, Gradl B, Palache B, Medema J. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 2006; 24(47-48):6812-22.
  • de Waure C, Veneziano MA, Cadeddu C, Capizzi S, Specchia ML, Capri S, Ricciardi W. Economic value of influenza vaccination. Hum Vaccin Immunother 2012; 8(1):119-29; PMID:22251999; https://doi.org/10.4161/hv.8.1.18420.
  • Centers for Disease Control and Prevention. Vaccine effectiveness - How well does the flu vaccine work? Available from: https://www.cdc.gov/flu/about/qa/vaccineeffect.htm (accessed July 2017)
  • Measures of Public Health Impact. Available from: https://www.cdc.gov/ophss/csels/dsepd/ss1978/lesson3/section6.html [accessed July 2017].
  • Murphy K, Weaver C. Janeway's Immunobiology. New York; Garland Science; 2016, 9th edition 904p.
  • Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24(8):1159-69; PMID:16213065; https://doi.org/10.1016/j.vaccine.2005.08.105.
  • Moro-García MA, Alonso-Arias R, López-Larrea C. Molecular Mechanisms Involved in the Aging of the T-cell Immune Response. Current Genomics 2012; 13(8):589-602; PMID:23730199; https://doi.org/10.2174/138920212803759749.
  • Gomez CR, Boehmer ED, Kovacs EJ. The aging innate immune system. Curr Opin Immunol 2005; 17:457-62; PMID:16084711; https://doi.org/10.1016/j.coi.2005.07.013.
  • Vasselon T, Detmers PA. Toll Receptors: a central element in innate immune responses Infect Immun 2002; 70(3):1033-41; PMID:11854180; https://doi.org/10.1128/IAI.70.3.1033-1041.2002.
  • Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol 2002; 169:4697-701; PMID:12391175; https://doi.org/10.4049/jimmunol.169.9.4697.
  • Grewe M. Chronological ageing and photoageing of dendritic cells. Clin Exp Dermatol 2001; 26:608-12; PMID:11696065; https://doi.org/10.1046/j.1365-2230.2001.00898.x.
  • van Duin D, Shaw AC. Toll-like receptors in older adults. J Am Geriatr Soc 2007; 55:1438-44; PMID:17767688; https://doi.org/10.1111/j.1532-5415.2007.01300.x.
  • Effros RB, Walford RL. T-Cell Cultures and the Hayflick Limit. Human Immunology 1984; 9(1):49-65; PMID:6607244; https://doi.org/10.1016/0198-8859(84)90006-5.
  • Messaoudi I, Lemaoult J, Guevara-Patino JA, Metzner BM, Nikolich-Zugich J. Age-related CD8 T cell clonal expansions constrict CD8 T cell repertoire and have the potential to impair immune defense. J Exp Med 2004; 200(10):1347-58.
  • Yager EJ, Ahmed M, Lanzer K, Randall TD, Woodland DL, Blackman MA. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J Exp Med 2008; 205(3):711-23; PMID: 18332179; https://doi.org/10.1084/jem.20040437.
  • Murasko DM, Jiang J. Response of aged mice to primary virus infections. Immunol Rev 2005; 205:285-96; PMID:15882361; https://doi.org/10.1111/j.0105-2896.2005.00273.x.
  • Brien JD, Uhrlaub JL, Hirsch A, Wiley CA, Nikolich-Zugich J. Key role of T cell defects in age-related vulnerability to West Nile virus. J Exp Med 2009; 206(12):2735-45; PMID:19901080; https://doi.org/10.1084/jem.20090222.
  • Cicin-Sain L, Smyk-Pearson S, Currier N, Byrd L, Koudelka C, Robinson T, Swarbrick G, Tackitt S, Legasse A, Fischer M, et al. Loss of naive T cells and repertoire constriction predict poor response to vaccination in old primates. J Immunol 2010; 184(12):6739-45; PMID:20483749; https://doi.org/10.4049/jimmunol.0904193.
  • Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-69; PMID:16213065; https://doi.org/10.1016/j.vaccine.2005.08.105.
  • Weinberger B, Dietmar Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008; 46(7):1078-84; PMID:18444828; https://doi.org/10.1086/529197.
  • Hsu HC, Scott DK, Mountz JD. Impaired apoptosis and immune senescence - cause or effect? Immunol Rev 2005; 205:130-46; PMID:15882350; https://doi.org/10.1111/j.0105-2896.2005.00270.x.
  • Haynes L, Linton PJ, Eaton SM, Tonkonogy SL, Swain SL. Interleukin 2, but not other common gamma chain-binding cytokines, can reverse the defect in generation of CD4 effector T cells from naive T cells of aged mice. J Exp Med 1999; 190(7):1013-24; PMID:10510091; https://doi.org/10.1084/jem.190.7.1013.
  • Eaton ME, Burns EM, Kusser K, Randall TD, Haynes L. Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J Exp Med 2004; 200(12):1613-22; PMID:15611289; https://doi.org/10.1084/jem.20041395.
  • McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013; 13(6):485-96; PMID:23518156; https://doi.org/10.1016/S1473-3099(13)70046-X.
  • Stokes J, Chenoweth AD, Waltz AD, Gladen RG, Shaw D. Results of immunization by means of active virus of human influenza. J Clin Invest 1937; 16:237-43; PMID:16694474; https://doi.org/10.1172/JCI100853.
  • Commission on Influenza: A clinical evaluation of vaccination against influenza. JAMA 1944; 124:982-5; https://doi.org/10.1001/jama.1944.62850140004008.
  • Davenport FM. Current knowledge of influenza vaccine. JAMA 1962; 182:11-3; PMID:13883724; https://doi.org/10.1001/jama.1962.03050400013003.
  • ECDC. Influenza vaccination. Available from: http://ecdc.europa.eu/en/healthtopics/seasonal_influenza/vaccines/Pages/influenza_vaccination.aspx (accessed July 2017)
  • Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015–16 influenza season. Morb Mortal Wkly Rep 2015; 64:818-25; https://doi.org/10.15585/mmwr.mm6430a3.
  • WHO. Meeting of the strategic advisory group of experts on immunization, April 2012 – conclusions and recommendations. Morbid Mortal Wkly Rep 2012; 87(21):201-16.
  • MacIntyre CR, Heywood AE, Kovoor P, Ridda I, Seale H, Tan T, Gao Z, Katelaris AL, Siu HW, Lo V, et al. Ischaemic heart disease, influenza and influenza vaccination: a prospective case control study. Heart 2013; 99:1843-8; PMID:23966030; https://doi.org/10.1136/heartjnl-2013-304320.
  • MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart 2016; 102(24):1953-6; PMID:27686519; https://doi.org/10.1136/heartjnl-2016-309983.
  • Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immune response to seasonal influenza vaccination in older adults: A systems biology approach. Expert Rev Vaccines 2012; 11(8):985–994; https://doi.org/10.1586/erv.12.61
  • Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo F, Garcia Cenoz M, Guevara M, Moran J, Irisarri F, Arriazu M, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 2013; 18(5): pii=20388. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20388
  • Pebody RG, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson CI, Robertson C, Cottrell S, Smyth B, Zambon M, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: Evidence of waning intra-seasonal protection. Euro Surveill 2013; 18(5):pii=20389. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20389
  • Young B, Xiahong Z, Cook AR, Parry CM, Smith AW, I-Cheng MC. Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. Vaccine 2017; 35:212-221; PMID:27939013; https://doi.org/10.1016/j.vaccine.2016.11.013.
  • Manzoli L, Ioannidis JP, Flacco ME, De Vito C, Villari P. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 metaanalyses. Hum Vaccin Immunother 2012; 8:851-62; PMID:22777099; https://doi.org/10.4161/hv.19917.
  • Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7:658-66; PMID:17897608; https://doi.org/10.1016/S1473-3099(07)70236-0.
  • Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006; 35:337-44; PMID:16368725; https://doi.org/10.1093/ije/dyi274.
  • European Centre for Disease and Control (ECDC), Angus N, Tsolova S. In: ECDC, ed. Priority risk groups for influenza vaccination. 2008. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0808_GUI_Priority_Risk_Groups_for_Influenza_Vaccination.pdf (accessed July 2017)
  • Fleming DM, Elliot AJ. Estimating the risk population in relation to influenzavaccination policy. Vaccine 2006; 24(May (20):4378-85; PMID:16574281; https://doi.org/10.1016/j.vaccine.2006.02.053.
  • Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec 2012; 87:461-76; PMID:23210147.
  • Mereckiene J, Cotter S, Nicoll A, Lopalco P, Noori T, Weber J, D'Ancona F, Levy-Bruhl D, Dematte L, Giambi C, et al. VENICE Project Gatekeepers Group. Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). Euro Surveill 2014; 19:20780; PMID:24786262; https://doi.org/10.2807/1560-7917.ES2014.19.16.20780.
  • CDC. Prevention and Control of Seasonal Influenza with Vaccines Recommendations of the Advisory Committee on Immunization Practices — United States, 2016–17 Influenza Season. Morbid Mortal Weekly Rep 2016; 65(5):1-52.
  • ECDC. Vaccine schedule. Recommended immunisations for influenza. Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx (accessed January 2017)
  • Ministry of Healthcare of the Russian Federation. Influenza vaccine. Available from: http://www.influenza.spb.ru/en/science_and_society/influenza_vaccines/ (accessed January 2017)
  • Australian Institute of Health and Welfare 2011. 2009 Adult Vaccination Survey: Summary results. Cat. no. PHE 135. Canberra: AIHW. Available from: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737418286 (accessed July 2017)
  • Fiore AE, Bridges CB, Katz JM, Cox NJ. Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines, 6th edition. Philadelphia: Elsevier Saunders; 2013; p. 257–293
  • Thomas-Crusells J, McElhaney JE, Aguado MT. Report of the ad-hoc consultation on aging and immunization for a future WHO research agenda on life-course immunization. Vaccine 2012; 30:6007-12; PMID:22835737; https://doi.org/10.1016/j.vaccine.2012.07.025.
  • Palache A, Oriol-Mathieu V, Fino M, Xydia-Charmanta M. Seasonal influenza vaccine dose distribution in 195 countries (2004–2013): little progress in estimated global vaccination coverage. Vaccine 2015; 33:5598-605; PMID:26368399; https://doi.org/10.1016/j.vaccine.2015.08.082.
  • Karki S, Dyda A, Newall A, Heywood A, MacIntyre CR, McIntyre P, Banks E, Liu B. Comparison of influenza vaccination coverage between immigrant and Australian-born adults. Vaccine 2016; 34:6388-95; PMID:27742215; https://doi.org/10.1016/j.vaccine.2016.10.012.
  • Kwon DS, Kim K, Park SM. Factors associated with influenza vaccination coverage among the elderly in South Korea: the Fourth Korean National Health and Nutrition Examination Survey. MBJ Open 2016; 6:e012618.
  • CDC. Surveillance of Vaccination Coverage Among Adult Population – United States, 2014. Morbid Mortal Weekly Rep 2016; 65(1):1-38.
  • Giese C, Mereckiene J, Danis K, O'Donnell J, O'Flanagan D, Cotter S. Low vaccination coverage for seasonal influenza and pneumococcaldisease among adults at-risk and health care workers in Ireland, 2013:The key role of GPs in recommending vaccination. Vaccine 2016; 34:3657-62; PMID:27255466; https://doi.org/10.1016/j.vaccine.2016.05.028.
  • Gasparini R, Amicizia D, Lai PL, Panatto D. Influenza vaccination: from epidemiological aspects and advances in research to dissent and vaccination policies. J Prev Med Hyg 2016; 57:E1-4; PMID:27346933.
  • Buchan SA, Kwong JC. Trends in influenza vaccine coverage and vaccine hesitancy in Canada, 2006/07 to 2013/14: results from cross-sectional survey data. CMAJ Open 2016; 4(3):E455-62; PMID:27975047; https://doi.org/10.9778/cmajo.20160050.
  • Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; (7): CD001269. PMID:20614424
  • Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010; (2); PMID:20166072; https://doi.org/10.1002/14651858.CD004876.pub3
  • Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine 2013; 31(50):6030-3; PMID:24095882; https://doi.org/10.1016/j.vaccine.2013.09.063.
  • Van-Tam J. Are influenza vaccines effective for the elderly? 4th ESWI Science Policy Flu Summit, Brussels, September 2015
  • Govaert TM, Dinant GJ, Aretz K, Masurel N, Sprenger MJ, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 1993; 307(6910):988-90; PMID:8241913; https://doi.org/10.1136/bmj.307.6910.988.
  • Barry DW, Mayner RE, Hochstein HD, Dunlap RC, Rastogi SC, Hannah JE, Blackburn RJ, Sullivan JL, Gerety RJ. Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. Am J Epidemiol 1976; 104(1):47-59; PMID:132867; https://doi.org/10.1093/oxfordjournals.aje.a112273.
  • Rowhani-Rahbar A, Klein NP, Baxter R. Assessing the safety of influenza vaccination in specific populations children and the elderly. Expert Rev Vaccines 2012; 11(8):973-984.
  • Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, Cho GJ, Hwang TG, Kim WJ. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine 2010; 28:3929-35; PMID:23002978; https://doi.org/10.1586/erv.12.66.
  • Castilla J, Martínez-Baz I, Martínez-Artola V, Reina G, Pozo F, García Cenoz M, Guevara M, Morán J, Irisarri F, Arriazu M, et al. Primary Health Care Sentinel Network; Network for Influenza Surveillance in Hospitals of Navarre. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 2013; 18:20388; PMID:23399423.
  • Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine 2015; 33:246-51; https://doi.org/10.1016/j.vaccine.2014.06.052.
  • Harada Y, Ninomiya-Mori A, Takahashi Y, Shirakura M, Kishida N, Kageyama T, Tada Y, Tashiro M, Odagiri T. Inactivated and adjuvanted whole-virion clade 2.3. 4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice. Vaccine 2011; 29:8330-7; https://doi.org/10.1016/j.vaccine.2011.08.091.
  • Ninomiya A, Imai M, Tashiro M, Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007; 25:3554-60; PMID:17293015; https://doi.org/10.1016/j.vaccine.2007.01.083.
  • Nolan TM, Richmond PC, Skeljo MV, Pearce G, Hartel G, Formica NT, Hoschler K, Bennet J, Ryan D, Papanaoum K, et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine. 2008; 26:4160-7; PMID:18599164; https://doi.org/10.1016/j.vaccine.2008.05.077.
  • Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, Zhang XF, Pan HX, Meng FY, Hu YM, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361:2414-23; PMID:19846844; https://doi.org/10.1056/NEJMoa0908535.
  • Maue AC, Eaton SM, Lanthier PA, Sweet KB, Blumerman SL, Haynes L. Proinflammatory adjuvants enhance the cognate helper activity of aged CD4 T cells. J Immunol 2009; 182:6129-35; PMID:19414765; https://doi.org/10.4049/jimmunol.0804226.
  • Diebold SS. Determination of T-cell fate by dendritic cells. Immunol Cell Biol 2008; 86:389-97; PMID:18382438; https://doi.org/10.1038/icb.2008.26.
  • Powers DC, Fries LF, Murphy BR, Thumar B, Clements ML. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J Clin Microbiol 1991; 29:498–505; PMID:2037667
  • Durando P, Iudici R, Alicino C, Alberti M, de Florentis D, Ansaldi F, Icardi G. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum Vaccin 2011; 7(Suppl):29-40; PMID:21245655; https://doi.org/10.4161/hv.7.0.14560.
  • Ansaldi F, Orsi A, de FD, Parodi V, Rappazzo E, Coppelli M, Durando P, Icardi G. Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: Evaluation of immunogenicity, cross-protection, safety and tolerability. Hum Vaccin Immunother. 2013; 9:591-8; PMID:23295262; https://doi.org/10.4161/hv.23240.
  • Holland D, Booy R, De LF, Eizenberg P, McDonald J, Karrasch J, McKeirnan M, Salem H, Mills G, Reid J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 2008; 198:650-658; PMID:18652550; https://doi.org/10.1086/590434.
  • Marra F, Young F, Richardson K, Marra CA. A Meta-analysis of intradermal versus intramuscular influenza vaccines: Immunogenicity and Adverse Events. Influenza Other Respir Viruses 2013; 7(4):584-603.
  • DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009–2010 season. Vaccine 2013; 31:861-6; PMID:23261045; https://doi.org/10.1111/irv.12000.
  • Chen WH, Cross AS, Edelman R, Sztein MB, Blackwelder WC, Pasetti MF. Antibody and Th1- type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. Vaccine 2011; 29:2865-73; PMID:21352939; https://doi.org/10.1016/j.vaccine.2011.02.017.
  • Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172-80; PMID:19508159; https://doi.org/10.1086/599790.
  • Keitel WA, Atmar RL, Cate TR, Petersen NJ, Greenberg SB, Ruben F, Couch RB. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-7; PMID:16717175; https://doi.org/10.1001/archinte.166.10.1121.
  • McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176(10):6333-9; PMID:16670345; https://doi.org/10.4049/jimmunol.176.10.6333.
  • Gorse GJ, O'Connor TZ, Newman FK, Mandava MD, Mendelman PM, Wittes J, Peduzzi PN. Immunity to influenza in older adults with chronic obstructive pulmonary disease. J Infect Dis 2004; 190:11-9; PMID:15195238; https://doi.org/10.1086/421121.
  • Doucet JD, Forget MA, Grange C, Rouxel RN, Arbour N, von MV, Lapointe R. Endogenously expressed matrix protein M1 and nucleoprotein of influenza A are efficiently presented by class I and class II major histocompatibility complexes. J Gen Virol 2011; 92:1162-71; PMID:21307226; https://doi.org/10.1099/vir.0.029777-0.
  • Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011; 52:1-7; PMID:21148512; https://doi.org/10.1093/cid/ciq015.
  • Antrobus RD, Lillie PJ, Berthoud TK, Spencer AJ, McLaren JE, Ladell K, Lambe T, Milicic A, Price DA, Hill AV, et al. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One 2012; 7:e48322; PMID:23118984; https://doi.org/10.1371/journal.pone.0048322.
  • Oeppen J, Vaupel JW. Demography. Broken limits to life expectancy. Science 2002; 296(5570):1029-31; PMID:12004104; https://doi.org/10.1126/science.1069675.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.